克拉屈滨加阿糖胞苷加维奈克拉治疗对维奈克拉加去甲基化药物难治或复发的急性髓系白血病 - Suppr | 超能文献

Cladribine plus cytarabine plus venetoclax in acute myeloid leukemia relapsed or refractory to venetoclax plus hypomethylating agent.

作者信息

Steinauer Nickolas, McCullough Kristen, Al-Kali Aref, Alkhateeb Hassan B, Begna Kebede H, Mangaonkar Abhishek A, Saliba Antoine N, Torghabeh Mehrdad, Litzow Mark R, Hogan William J, Shah Mithun, Patnaik Mrinal M, Pardanani Animesh, Badar Talha, Murthy Hemant, Foran James, Yi Cecilia Arana, Tefferi Ayalew, Gangat Naseema

机构信息

Division of Hematology, Mayo Clinic, Rochester, MN.

Division of Hematology, Mayo Clinic, Jacksonville, FL.

出版信息

Haematologica. 2024 Aug 1;109(8):2706-2710. doi: 10.3324/haematol.2024.284962.

DOI:10.3324/haematol.2024.284962

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11290516/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e475/11290516/b35743da9b33/1092706.fig1.jpg

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Cladribine plus cytarabine plus venetoclax in acute myeloid leukemia relapsed or refractory to venetoclax plus hypomethylating agent.

Haematologica. 2024 Aug 1;109(8):2706-2710. doi: 10.3324/haematol.2024.284962.

2

Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial.

Lancet Haematol. 2021 Aug;8(8):e552-e561. doi: 10.1016/S2352-3026(21)00192-7.

3

Treatment of refractory acute myeloid leukaemia during pregnancy with venetoclax, high-dose cytarabine and mitoxantrone.

Br J Haematol. 2021 Jan;192(2):e60-e63. doi: 10.1111/bjh.17220. Epub 2020 Nov 21.

4

Efficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia.

Haematologica. 2018 Sep;103(9):e404-e407. doi: 10.3324/haematol.2018.188094. Epub 2018 Mar 15.

5

Venetoclax in combination with cytarabine with or without idarubicin in children with relapsed or refractory acute myeloid leukaemia: a phase 1, dose-escalation study.

Lancet Oncol. 2020 Apr;21(4):551-560. doi: 10.1016/S1470-2045(20)30060-7. Epub 2020 Mar 11.

6

Venetoclax combined with daunorubicin and cytarabine (2 + 6) in acute myeloid leukemia: Updated results of a phase II trial.

Hematol Oncol. 2024 Jul;42(4):e3296. doi: 10.1002/hon.3296.

7

Venetoclax plus hypomethylating agents or low-dose cytarabine in acute myeloid leukemia: all that glitters is gold?

Blood Cancer J. 2020 Jan 28;10(1):10. doi: 10.1038/s41408-020-0281-x.

8

Lower intensity therapy with cladribine/low dose cytarabine/venetoclax in older patients with acute myeloid leukemia compares favorably with intensive chemotherapy among patients undergoing allogeneic stem cell transplantation.

Cancer. 2024 Oct 1;130(19):3333-3343. doi: 10.1002/cncr.35388. Epub 2024 May 29.

9

Venetoclax as monotherapy and in combination with hypomethylating agents or low dose cytarabine in relapsed and treatment refractory acute myeloid leukemia: a systematic review and meta-analysis.

Haematologica. 2020 Nov 1;105(11):2659-2663. doi: 10.3324/haematol.2019.242826.

10

Outcome of secondary acute myeloid leukemia treated with hypomethylating agent plus venetoclax (HMA-Ven) or liposomal daunorubicin-cytarabine (CPX-351).

Am J Hematol. 2021 Jun 1;96(6):E196-E200. doi: 10.1002/ajh.26157. Epub 2021 Apr 8.

引用本文的文献

1

Outcomes for Patients With Myeloid Neoplasms Treated With Chemotherapy Plus Venetoclax After Prior Venetoclax Therapy.

EJHaem. 2025 Jun 13;6(3):e70078. doi: 10.1002/jha2.70078. eCollection 2025 Jun.

2

Efficacy and safety of cladribine, low-dose cytarabine and venetoclax in newly diagnosed and relapsed/refractory acute myeloid leukemia: results of a single center study.

Ann Hematol. 2025 May;104(5):2745-2753. doi: 10.1007/s00277-025-06389-9. Epub 2025 May 20.

本文引用的文献

1

Efficacy and safety of cladribine, low-dose cytarabine and venetoclax in relapsed/refractory acute myeloid leukemia: results of a pilot study.

Blood Cancer J. 2024 Jan 18;14(1):12. doi: 10.1038/s41408-024-00982-3.

2

A Novel Type of Monocytic Leukemia Stem Cell Revealed by the Clinical Use of Venetoclax-Based Therapy.

Cancer Discov. 2023 Sep 6;13(9):2032-2049. doi: 10.1158/2159-8290.CD-22-1297.

3

Outcome of patients with acute myeloid leukemia following failure of frontline venetoclax plus hypomethylating agent therapy.

Haematologica. 2023 Nov 1;108(11):3170-3174. doi: 10.3324/haematol.2022.282677.

4

Implications of RAS mutational status in subsets of patients with newly diagnosed acute myeloid leukemia across therapy subtypes.

Am J Hematol. 2022 Dec;97(12):1599-1606. doi: 10.1002/ajh.26731. Epub 2022 Oct 19.

5

Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN.

Blood. 2022 Sep 22;140(12):1345-1377. doi: 10.1182/blood.2022016867.

6

Phase II Study of Venetoclax Added to Cladribine Plus Low-Dose Cytarabine Alternating With 5-Azacitidine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia.

J Clin Oncol. 2022 Nov 20;40(33):3848-3857. doi: 10.1200/JCO.21.02823. Epub 2022 Jun 15.

7

Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia.

N Engl J Med. 2020 Aug 13;383(7):617-629. doi: 10.1056/NEJMoa2012971.

8

Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens.

Haematologica. 2021 Mar 1;106(3):894-898. doi: 10.3324/haematol.2020.252569.

9

Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML.

Blood. 2020 Mar 12;135(11):791-803. doi: 10.1182/blood.2019003988.